probenecid has been researched along with Ventricular Dysfunction, Left in 1 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Ventricular Dysfunction, Left: A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Re-Prosper-HF study (Repurposing Probenecid for the Treatment of Heart Failure with Reduced Ejection Fraction) is a three-site double-blinded randomized-controlled trial that will test the hypothesis that probenecid can improve cardiac function in patients with HFrEF." | 9.51 | Repurposing Probenecid for the Treatment of Heart Failure (Re-Prosper-HF): a study protocol for a randomized placebo-controlled clinical trial. ( Bunke, J; Evans, K; Foster, G; Joseph, J; Luo, X; Mcconeghy, K; Onadeko, T; Parent, M; Robbins, N; Rubinstein, J; Wu, WC, 2022) |
| "The Re-Prosper-HF study (Repurposing Probenecid for the Treatment of Heart Failure with Reduced Ejection Fraction) is a three-site double-blinded randomized-controlled trial that will test the hypothesis that probenecid can improve cardiac function in patients with HFrEF." | 5.51 | Repurposing Probenecid for the Treatment of Heart Failure (Re-Prosper-HF): a study protocol for a randomized placebo-controlled clinical trial. ( Bunke, J; Evans, K; Foster, G; Joseph, J; Luo, X; Mcconeghy, K; Onadeko, T; Parent, M; Robbins, N; Rubinstein, J; Wu, WC, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rubinstein, J | 1 |
| Robbins, N | 1 |
| Evans, K | 1 |
| Foster, G | 1 |
| Mcconeghy, K | 1 |
| Onadeko, T | 1 |
| Bunke, J | 1 |
| Parent, M | 1 |
| Luo, X | 1 |
| Joseph, J | 1 |
| Wu, WC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Veterans With Heart Failure With Reduced Ejection Fraction With Probenecid[NCT04551222] | Phase 2/Phase 3 | 120 participants (Anticipated) | Interventional | 2021-06-09 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for probenecid and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Repurposing Probenecid for the Treatment of Heart Failure (Re-Prosper-HF): a study protocol for a randomized placebo-controlled clinical trial.
Topics: Calcium; Heart Failure; Humans; Probenecid; Randomized Controlled Trials as Topic; Stroke Volume; Ve | 2022 |